147 related articles for article (PubMed ID: 38267516)
1. GlioPredictor: a deep learning model for identification of high-risk adult IDH-mutant glioma towards adjuvant treatment planning.
Zheng S; Rammohan N; Sita T; Teo PT; Wu Y; Lesniak M; Sachdev S; Thomas TO
Sci Rep; 2024 Jan; 14(1):2126. PubMed ID: 38267516
[TBL] [Abstract][Full Text] [Related]
2. IDH1
Han X; Zhou H; Sun W; Hou L; Wang Y; Wang H; Lv Z; Xue X
Sci Rep; 2023 Nov; 13(1):19659. PubMed ID: 37952042
[TBL] [Abstract][Full Text] [Related]
3. Targetable signaling pathway mutations are associated with malignant phenotype in IDH-mutant gliomas.
Wakimoto H; Tanaka S; Curry WT; Loebel F; Zhao D; Tateishi K; Chen J; Klofas LK; Lelic N; Kim JC; Dias-Santagata D; Ellisen LW; Borger DR; Fendt SM; Vander Heiden MG; Batchelor TT; Iafrate AJ; Cahill DP; Chi AS
Clin Cancer Res; 2014 Jun; 20(11):2898-909. PubMed ID: 24714777
[TBL] [Abstract][Full Text] [Related]
4. Isocitrate dehydrogenase-mutant glioma: Evolving clinical and therapeutic implications.
Miller JJ; Shih HA; Andronesi OC; Cahill DP
Cancer; 2017 Dec; 123(23):4535-4546. PubMed ID: 28980701
[TBL] [Abstract][Full Text] [Related]
5. Identification of a Prognostic Hypoxia-Associated Gene Set in IDH-Mutant Glioma.
Dao Trong P; Rösch S; Mairbäurl H; Pusch S; Unterberg A; Herold-Mende C; Warta R
Int J Mol Sci; 2018 Sep; 19(10):. PubMed ID: 30257451
[TBL] [Abstract][Full Text] [Related]
6. TERT promoter mutation status is necessary and sufficient to diagnose IDH-wildtype diffuse astrocytic glioma with molecular features of glioblastoma.
Fujimoto K; Arita H; Satomi K; Yamasaki K; Matsushita Y; Nakamura T; Miyakita Y; Umehara T; Kobayashi K; Tamura K; Tanaka S; Higuchi F; Okita Y; Kanemura Y; Fukai J; Sakamoto D; Uda T; Machida R; Kuchiba A; Maehara T; Nagane M; Nishikawa R; Suzuki H; Shibuya M; Komori T; Narita Y; Ichimura K
Acta Neuropathol; 2021 Aug; 142(2):323-338. PubMed ID: 34148105
[TBL] [Abstract][Full Text] [Related]
7. Genomic Prognosticators and Extent of Resection in Molecularly Subtyped World Health Organization Grade II and III Gliomas-A Single-Institution, Nine-Year Data.
Lasica AB; Jaunmuktane Z; Fersht N; Kirkman MA; Dixon L; Hoskote C; Brandner S; Samandouras G
World Neurosurg; 2021 Jul; 151():e217-e233. PubMed ID: 33866029
[TBL] [Abstract][Full Text] [Related]
8. Isocitrate Dehydrogenase Mutations are Better Prognostic Marker than O6-methylguanine-DNA Methyltransferase Promoter Methylation in Glioblastomas - a Retrospective, Single-centre Molecular Genetics Study of Gliomas.
Houdova Megova M; Drábek J; Dwight Z; Trojanec R; Koudeláková V; Vrbková J; Kalita O; Mlcochova S; Rabcanova M; Hajdúch M
Klin Onkol; 2017; 30(5):361-371. PubMed ID: 29031038
[TBL] [Abstract][Full Text] [Related]
9. IDH1/2 gene status defines the prognosis and molecular profiles in patients with grade III gliomas.
Shibahara I; Sonoda Y; Kanamori M; Saito R; Yamashita Y; Kumabe T; Watanabe M; Suzuki H; Kato S; Ishioka C; Tominaga T
Int J Clin Oncol; 2012 Dec; 17(6):551-61. PubMed ID: 21971842
[TBL] [Abstract][Full Text] [Related]
10. Comprehensive Genomic Analysis in NRG Oncology/RTOG 9802: A Phase III Trial of Radiation Versus Radiation Plus Procarbazine, Lomustine (CCNU), and Vincristine in High-Risk Low-Grade Glioma.
Bell EH; Zhang P; Shaw EG; Buckner JC; Barger GR; Bullard DE; Mehta MP; Gilbert MR; Brown PD; Stelzer KJ; McElroy JP; Fleming JL; Timmers CD; Becker AP; Salavaggione AL; Liu Z; Aldape K; Brachman DG; Gertler SZ; Murtha AD; Schultz CJ; Johnson D; Laack NN; Hunter GK; Crocker IR; Won M; Chakravarti A
J Clin Oncol; 2020 Oct; 38(29):3407-3417. PubMed ID: 32706640
[TBL] [Abstract][Full Text] [Related]
11. Isocitrate dehydrogenase (IDH) status prediction in histopathology images of gliomas using deep learning.
Liu S; Shah Z; Sav A; Russo C; Berkovsky S; Qian Y; Coiera E; Di Ieva A
Sci Rep; 2020 May; 10(1):7733. PubMed ID: 32382048
[TBL] [Abstract][Full Text] [Related]
12. Use of telomerase promoter mutations to mark specific molecular subsets with reciprocal clinical behavior in IDH mutant and IDH wild-type diffuse gliomas.
Akyerli CB; Yüksel Ş; Can Ö; Erson-Omay EZ; Oktay Y; Coşgun E; Ülgen E; Erdemgil Y; Sav A; von Deimling A; Günel M; Yakıcıer MC; Pamir MN; Özduman K
J Neurosurg; 2018 Apr; 128(4):1102-1114. PubMed ID: 28621624
[TBL] [Abstract][Full Text] [Related]
13. Prognostic role of mitochondrial pyruvate carrier in isocitrate dehydrogenase-mutant glioma.
Karsy M; Guan J; Huang LE
J Neurosurg; 2018 Mar; 130(1):56-66. PubMed ID: 29547090
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of MTAP and p16 immunohistochemical deficiency as surrogate marker for CDKN2A/B homozygous deletion in gliomas.
Maragkou T; Reinhard S; Jungo P; Pasquier B; Neuenschwander M; Schucht P; Vassella E; Hewer E
Pathology; 2023 Jun; 55(4):466-477. PubMed ID: 37032198
[TBL] [Abstract][Full Text] [Related]
15. Transcriptomic Landscape of Lower Grade Glioma Based on Age-Related Non-Silent Somatic Mutations.
Park Y; Park J; Ahn JW; Sim JM; Kang SJ; Kim S; Hwang SJ; Han SH; Sung KS; Lim J
Curr Oncol; 2021 Jun; 28(3):2281-2295. PubMed ID: 34205437
[TBL] [Abstract][Full Text] [Related]
16. A novel MRI-based deep learning networks combined with attention mechanism for predicting CDKN2A/B homozygous deletion status in IDH-mutant astrocytoma.
Zhang L; Wang R; Gao J; Tang Y; Xu X; Kan Y; Cao X; Wen Z; Liu Z; Cui S; Li Y
Eur Radiol; 2024 Jan; 34(1):391-399. PubMed ID: 37553486
[TBL] [Abstract][Full Text] [Related]
17. Correlation of Molecular Markers in High Grade Gliomas with Response to Chemo-Radiation.
Khurana R; Rath S; Singh HB; Rastogi M; Nanda SS; Chauhan A; Kaif M; Hussain N
Asian Pac J Cancer Prev; 2020 Mar; 21(3):755-760. PubMed ID: 32212804
[TBL] [Abstract][Full Text] [Related]
18. Characteristics of IDH-mutant gliomas with non-canonical IDH mutation.
Poetsch L; Bronnimann C; Loiseau H; Frénel JS; Siegfried A; Seizeur R; Gauchotte G; Cappellen D; Carpentier C; Figarella-Branger D; Eimer S; Meyronet D; Ducray F;
J Neurooncol; 2021 Jan; 151(2):279-286. PubMed ID: 33205355
[TBL] [Abstract][Full Text] [Related]
19. The comparison of clinical and biological characteristics between IDH1 and IDH2 mutations in gliomas.
Wang HY; Tang K; Liang TY; Zhang WZ; Li JY; Wang W; Hu HM; Li MY; Wang HQ; He XZ; Zhu ZY; Liu YW; Zhang SZ
J Exp Clin Cancer Res; 2016 May; 35():86. PubMed ID: 27245697
[TBL] [Abstract][Full Text] [Related]
20. Granular cell astrocytoma: an aggressive IDH-wildtype diffuse glioma with molecular genetic features of primary glioblastoma.
Vizcaino MA; Palsgrove DN; Yuan M; Giannini C; Cabrera-Aldana EE; Pallavajjala A; Burger PC; Rodriguez FJ
Brain Pathol; 2019 Mar; 29(2):193-204. PubMed ID: 30222900
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]